Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease (CHIMICI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03376230|
Recruitment Status : Recruiting
First Posted : December 18, 2017
Last Update Posted : December 18, 2017
Inflammatory Bowel Diseases (IBD) including Crohn's disease and ulcerative colitis are multifactorial diseases leading to chronic inflammation of intestinal mucosa. Their etiology is still unknown. Recently, major advances in the understanding of their pathophysiology have allowed to define them as heterogenic polygenic diseases, occurring in genetically susceptible patients. However, the whole genetic susceptibility does not explain the development of IBD and several data argue in favor of the involvement of environmental factors, which remain to be identified.
The aims of this clinical trial are:
- As main objective: To determine the effects of environmental pollutants on intestinal homeostasis and particularly on inflammatory process and endoplasmic reticulum stress.
- As secondary objective, to assess in human the genetic susceptibility of intestinal mucosa to environmental chemical compounds (I.e. xenobiotics), its interindividual variability, and its potential involvement in the pathogenesis of IBD.
|Condition or disease||Intervention/treatment|
|Inflammatory Bowel Diseases||Other: Collect of blood, urines, and intestinal biopsies|
|Study Type :||Observational|
|Estimated Enrollment :||600 participants|
|Official Title:||Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease|
|Actual Study Start Date :||February 2010|
|Estimated Primary Completion Date :||January 24, 2019|
|Estimated Study Completion Date :||January 24, 2019|
|Control patients||Other: Collect of blood, urines, and intestinal biopsies|
|Crohn's disease patients||Other: Collect of blood, urines, and intestinal biopsies|
|Ulcerative colitis patients||Other: Collect of blood, urines, and intestinal biopsies|
- Comparison of inflammatory response of biopsies to pollutants between the 3 groups of patients. [ Time Frame: Baseline ]
- Comparison of expression pattern of genes involved in xenobiotics detoxification in intestinal mucosa in between the 3 groups of patients. [ Time Frame: Baseline ]
- Study of molecular origin and consequences of the genetic variability observed. [ Time Frame: Baseline ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376230
|Contact: Pierre Desreumeaux, MD,PhDemail@example.com|
|CHRU, Hôpital Claude Huriez||Recruiting|
|Principal Investigator: Pierre Desreumaux, MD,PhD|
|Principal Investigator:||Pierre Desreumeaux, MD, PhD||University Hospital, Lille|